Anticancer research · 2026
Prognostic Impact of Residual T and N Status After Neoadjuvant Therapy in Breast Cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fujioka Sae, Kashiwagi Shinichiro, Kikukawa Yuko, Watanabe Chika, Takada Koji, Tauchi Yukie, Ogisawa Kana, Shibutani Masatsune, Kinoshita Haruhito, Morisaki Tamami, Yoshimura Keiko
Аннотация
BACKGROUND/AIM: Residual disease after neoadjuvant systemic therapy (NST) is strongly associated with prognosis in breast cancer. However, currently available indices such as the Residual Cancer Burden (RCB) and Neo-Bioscore are complex and not readily applicable in daily clinical practice. This study aimed to evaluate the prognostic significance of residual tumor morphology using only pathological T and N factors as a simple and clinically implementable index.
PATIENTS AND METHODS: Among 327 patients who received NST at our institution, 174 non-pathological complete response (non-pCR) cases who underwent axillary lymph node dissection were analyzed. Patients were classified according to the presence or absence of residual T and/or N factors (ypT+/ypN+, ypT+/ypN-, ypT-/ypN+). Disease-free survival (DFS) and cancer-specific survival (CSS) were assessed using Kaplan-Meier and Cox regression analyses.
RESULTS: Patients who achieved pCR had significantly better DFS and CSS (p<0.001 and p=0.010, log-rank) than those with residual disease. Among the non-pCR cohort, the ypT+/ypN+ group showed markedly worse DFS and CSS (p= 0.010 and p<0.001, log-rank) than patients without simultaneous residual T and N positivity. Multivariate analysis confirmed that concurrent ypT and ypN positivity was an independent predictor of poor DFS (hazard ratio=0.33; 95% confidence interval=0.17-0.62; p<0.001), along with high Ki67 expression.
CONCLUSION: Residual T and N positivity after NST represents a simple yet powerful prognostic indicator in breast cancer. This two-factor classification, easily derived from routine pathology, may serve as a practical reference for post-NST risk stratification and inform decisions regarding additional adjuvant treatment.
PATIENTS AND METHODS: Among 327 patients who received NST at our institution, 174 non-pathological complete response (non-pCR) cases who underwent axillary lymph node dissection were analyzed. Patients were classified according to the presence or absence of residual T and/or N factors (ypT+/ypN+, ypT+/ypN-, ypT-/ypN+). Disease-free survival (DFS) and cancer-specific survival (CSS) were assessed using Kaplan-Meier and Cox regression analyses.
RESULTS: Patients who achieved pCR had significantly better DFS and CSS (p<0.001 and p=0.010, log-rank) than those with residual disease. Among the non-pCR cohort, the ypT+/ypN+ group showed markedly worse DFS and CSS (p= 0.010 and p<0.001, log-rank) than patients without simultaneous residual T and N positivity. Multivariate analysis confirmed that concurrent ypT and ypN positivity was an independent predictor of poor DFS (hazard ratio=0.33; 95% confidence interval=0.17-0.62; p<0.001), along with high Ki67 expression.
CONCLUSION: Residual T and N positivity after NST represents a simple yet powerful prognostic indicator in breast cancer. This two-factor classification, easily derived from routine pathology, may serve as a practical reference for post-NST risk stratification and inform decisions regarding additional adjuvant treatment.